Biomimetic nanocarriers loaded with temozolomide by cloaking brain-targeting peptides for targeting drug delivery system to promote anticancer effects in glioblastoma cells
Glioma is the leading cancer of the central nervous system (CNS). The efficacy of glioma treatment is significantly hindered by the presence of the blood-brain barrier (BBB) and blood-brain tumour barrier (BBTB), which prevent most drugs from entering the brain and tumours. Hence, we established a n...
Main Authors: | Huaming Chen, Yunhong Wang, Hai Wang, Kun Zhang, Yunfei Liu, Qiangfeng Li, Chengli Li, Zhonghui Wen, Ziyu Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024042877 |
Similar Items
-
Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma
by: Justyna Magdalena Przystal, et al.
Published: (2019-04-01) -
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01) -
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma
by: Le Huang, et al.
Published: (2022-11-01) -
Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01) -
Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in Glioblastoma
by: Chuanhe Yang, et al.
Published: (2021-09-01)